00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
12:58 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

Oxaliplatin- and dihydroartemesinin-loaded nanoparticles for colorectal cancer

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Mouse studies suggest nanoparticles loaded with oxaliplatin and dihydroartemesinin could help treat colorectal cancer. The nanoparticles consist of a core of oxaliplatin polymerized with zinc and are coated with...
00:29 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Syndax pauses entinostat-PD-1/PD-L1 combo program

Syndax said in its 4Q18 financial results that it will "defer advancement" of its program evaluating entinostat plus PD-1/PD-L1 inhibitors after the combinations missed the primary endpoints of improving progression-free survival (PFS) in a pair...
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
00:52 , Jan 18, 2019 |  BC Week In Review  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
20:50 , Jan 14, 2019 |  BC Extra  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Mouse studies suggest inhibiting tumor-associated macrophages (TAMs) with liposomal clodronate could help treat lung cancer. In a mouse model of Lewis lung carcinoma, a liposomal preparation of the bisphosphonate clodronate, which induces...
20:30 , Jan 4, 2019 |  BC Extra  |  Company News

Immunocore taps MedImmune's Jallal as CEO

TCR company Immunocore Ltd. (Abingdon, U.K.) hired Bahija Jallal as CEO. She was EVP of AstraZeneca plc (LSE:AZN; NYSE:AZN) and president of its MedImmune LLC subsidiary. Jallal, who joined MedImmune in 2006, oversaw the development...